• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Adv . Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking

tetano

Editor, Senior Moderator
Sci Adv


. 2021 Apr 14;7(16):eabf8711.
doi: 10.1126/sciadv.abf8711. Print 2021 Apr.
Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking


Marion Schuller[SUP] 1 [/SUP], Galen J Correy[SUP] 2 [/SUP], Stefan Gahbauer[SUP] 3 [/SUP], Daren Fearon[SUP] 4 [/SUP], Taiasean Wu[SUP] 5 6 [/SUP], Roberto Efra?n D?az[SUP] 2 7 [/SUP], Iris D Young[SUP] 2 8 [/SUP], Luan Carvalho Martins[SUP] 9 [/SUP], Dominique H Smith[SUP] 10 [/SUP], Ursula Schulze-Gahmen[SUP] 8 [/SUP], Tristan W Owens[SUP] 8 [/SUP], Ishan Deshpande[SUP] 8 [/SUP], Gregory E Merz[SUP] 8 [/SUP], Aye C Thwin[SUP] 8 [/SUP], Justin T Biel[SUP] 8 [/SUP], Jessica K Peters[SUP] 8 [/SUP], Michelle Moritz[SUP] 8 [/SUP], Nadia Herrera[SUP] 8 [/SUP], Huong T Kratochvil[SUP] 8 [/SUP], QCRG Structural Biology Consortium; Anthony Aimon[SUP] 4 [/SUP], James M Bennett[SUP] 11 [/SUP], Jose Brandao Neto[SUP] 4 [/SUP], Aina E Cohen[SUP] 12 [/SUP], Alexandre Dias[SUP] 4 [/SUP], Alice Douangamath[SUP] 4 [/SUP], Louise Dunnett[SUP] 4 [/SUP], Oleg Fedorov[SUP] 11 [/SUP], Matteo P Ferla[SUP] 13 [/SUP], Martin R Fuchs[SUP] 14 [/SUP], Tyler J Gorrie-Stone[SUP] 4 [/SUP], James M Holton[SUP] 12 15 16 [/SUP], Michael G Johnson[SUP] 17 [/SUP], Tobias Krojer[SUP] 11 18 [/SUP], George Meigs[SUP] 15 16 [/SUP], Ailsa J Powell[SUP] 4 [/SUP], Johannes Gregor Matthias Rack[SUP] 1 [/SUP], Victor L Rangel[SUP] 11 18 19 [/SUP], Silvia Russi[SUP] 12 [/SUP], Rachael E Skyner[SUP] 4 [/SUP], Clyde A Smith[SUP] 12 [/SUP], Alexei S Soares[SUP] 20 [/SUP], Jennifer L Wierman[SUP] 12 [/SUP], Kang Zhu[SUP] 1 [/SUP], Peter O'Brien[SUP] 21 [/SUP], Natalia Jura[SUP] 22 [/SUP], Alan Ashworth[SUP] 10 [/SUP], John J Irwin[SUP] 3 [/SUP], Michael C Thompson[SUP] 23 [/SUP], Jason E Gestwicki[SUP] 3 5 [/SUP], Frank von Delft[SUP] 24 11 18 25 [/SUP], Brian K Shoichet[SUP] 26 [/SUP], James S Fraser[SUP] 27 [/SUP], Ivan Ahel[SUP] 28 [/SUP]



Affiliations

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) macrodomain within the nonstructural protein 3 counteracts host-mediated antiviral adenosine diphosphate-ribosylation signaling. This enzyme is a promising antiviral target because catalytic mutations render viruses nonpathogenic. Here, we report a massive crystallographic screening and computational docking effort, identifying new chemical matter primarily targeting the active site of the macrodomain. Crystallographic screening of 2533 diverse fragments resulted in 214 unique macrodomain-binders. An additional 60 molecules were selected from docking more than 20 million fragments, of which 20 were crystallographically confirmed. X-ray data collection to ultra-high resolution and at physiological temperature enabled assessment of the conformational heterogeneity around the active site. Several fragment hits were confirmed by solution binding using three biophysical techniques (differential scanning fluorimetry, homogeneous time-resolved fluorescence, and isothermal titration calorimetry). The 234 fragment structures explore a wide range of chemotypes and provide starting points for development of potent SARS-CoV-2 macrodomain inhibitors.
 
Back
Top Bottom